Idex Corp /de/ (IEX) · Oct 28, 2026 · Earnings
Beat — Adjusted EPS $2.33 vs ~$2.24 consensus; sales $951.7M vs ~$934M
IDEX earnings beat on stronger sales, margins and cash flow, while AI-driven HST demand helped prompt another full-year guidance increase.
IDEX is a specialized engineered-products company using its 8020 operating model to concentrate resources in higher-growth markets; the current growth engine is Health & Science Technologies, where demand is tied to data-center power, semiconductors, space and defense.
The quarter cleared a high bar, not just the prior year. Adjusted diluted EPS was $2.33 versus a published consensus of roughly $2.24, while sales were $951.7 million versus roughly $934 million expected. The filing itself says results were “ahead of our expectations.” 〔0〕
| Metric | Q3 2026 | Q3 2025 | Change / comparison |
|---|---|---|---|
| Orders | $991.2M | $880.3M | +13% (Financial Highlights) |
| Net sales | $951.7M | $878.7M | +8%; above ~$934M consensus (Financial Highlights) |
| Adjusted diluted EPS | $2.33 | $2.03 | +$0.30; above ~$2.24 consensus (Financial Highlights) |
| Adjusted EBITDA | $264.8M | $239.8M | +10%; margin 27.8% vs. 27.3% (Adjusted EBITDA reconciliation) |
| Free cash flow | $214.3M | $188.7M | +14%; conversion 124% (Free cash flow reconciliation) |
The strongest part of the story remains HST, and the growth broadened beyond it. HST organic sales rose 13% and segment EBITDA margin expanded 110 basis points to 28.8%, with the company citing AI-driven data-center power and semiconductor demand. 〔1〕 FMT organic sales rose 4% and FSDP organic sales rose 6%, so this was not solely a one-segment result, although HST supplied most of the acceleration (Segment results — Health & Science Technologies, Fluid & Metering Technologies, and Fire & Safety/Diversified Products).
Margins and cash conversion make the beat more durable than a revenue-only surprise. Consolidated adjusted EBITDA margin increased to 27.8% from 27.3%, while gross margin rose 70 basis points on an adjusted basis. Operating cash flow increased to $239.5 million and free cash flow to $214.3 million, despite higher capital spending (Adjusted EBITDA reconciliation; Adjusted gross profit reconciliation; Cash Flow statement). The filing attributes margin expansion to volume leverage, productivity and favorable mix, while acknowledging continuing price/cost pressure. 〔2〕
The most important incremental signal is another full-year guidance increase. IDEX had already raised its outlook after the second quarter, so the direction was partly anticipated; this filing confirms that demand and execution are running ahead of the prior plan. 〔3〕 The release supplied here does not include the revised full-year figures, so the size of the increase cannot be assessed from this filing alone.
Bottom line: This is a genuine earnings beat with improving margins, strong cash generation and a second consecutive upward guidance signal. The news advances IDEX’s existing AI- and semiconductor-led growth story rather than creating a wholly new one, but the breadth and profitability of the quarter make the upgrade meaningful.
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!